{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:36:23Z","timestamp":1761514583264,"version":"3.41.2"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00751","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T05:41:10Z","timestamp":1590039670000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy, Safety, and Economics of Intravenous Levetiracetam for Status Epilepticus: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Zhan-Miao","family":"Yi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Li","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suo-Di","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/PCC.0b013e3181a0e1cf","article-title":"Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures","volume":"10","author":"Abend","year":"2009","journal-title":"Pediatr. Crit. Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa002141","article-title":"A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus","volume":"345","author":"Alldredge","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.eplepsyres.2015.04.003","article-title":"Intravenous levetiracetam treatment in status epilepticus: A prospective study","volume":"114","author":"Atmaca","year":"2015","journal-title":"Epilepsy Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00701-011-1144-9","article-title":"Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial","volume":"154","author":"Bahr","year":"2012","journal-title":"Acta Neurochir. (Wien)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1528-1167.2006.00959.x","article-title":"Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures","volume":"48","author":"Baulac","year":"2007","journal-title":"Epilepsia"},{"key":"B6","doi-asserted-by":"crossref","first-page":"P6.226","DOI":"10.1212\/WNL.88.16_supplement.P6.226","article-title":"Rhabdomyolysis-an unrecognized adverse effect of Levetiracetam","volume":"88","author":"Bernatowicz","year":"2017","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1007\/s00415-009-5166-7","article-title":"Intravenous levetiracetam as treatment for status epilepticus","volume":"256","author":"Berning","year":"2009","journal-title":"J. Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","article-title":"Status epilepticus in adults","volume":"14","author":"Betjemann","year":"2015","journal-title":"Lancet Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000166610","article-title":"Intravenous levetiracetam for epileptic seizure emergencies in older people","volume":"55","author":"Beyenburg","year":"2009","journal-title":"Gerontology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.yebeh.2016.09.030","article-title":"Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus","volume":"64","author":"Brigo","year":"2016","journal-title":"Epilepsy Behav."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","article-title":"Guidelines for the evaluation and management of status epilepticus","volume":"17","author":"Brophy","year":"2012","journal-title":"Neurocrit. Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/epi.12307","article-title":"Treatment of convulsive status epilepticus in childhood: recommendations of the Italian League Against Epilepsy","volume":"54","author":"Capovilla","year":"2013","journal-title":"Epilepsia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jocn.2014.12.013","article-title":"Levetiracetam versus phenytoin in management of status epilepticus","volume":"22","author":"Chakravarthi","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/S0140-6736(19)30722-6","article-title":"Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial","volume":"393","author":"Dalziel","year":"2019","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/j.1528-1167.2010.02519.x","article-title":"High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy","volume":"51","author":"Depositario-Cabacar","year":"2010","journal-title":"Epilepsia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2014.00011","article-title":"Mechanisms of levetiracetam in the control of status epilepticus and epilepsy","volume":"5","author":"Deshpande","year":"2014","journal-title":"Front. Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1002\/mus.25548","article-title":"Rhabdomyolysis associated with levetiracetam administration","volume":"56","author":"Di Lorenzo","year":"2017","journal-title":"Muscle Nerve"},{"key":"B18","article-title":"Second Generation Anticonvulsants: Gabapentin, Lamotrigine, Levetiracetam, and Topiramate","volume-title":"Critical Care Toxicology.","author":"Emswiler","year":"2017"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1111\/j.1528-1167.2006.00850.x","article-title":"Use of levetiracetam in hospitalized patients","volume":"47","author":"Falip","year":"2006","journal-title":"Epilepsia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.12809\/hkmj166025","article-title":"Review and update of the Hong Kong Epilepsy Guideline on status epilepticus","volume":"23","author":"Fung","year":"2017","journal-title":"Hong Kong Med. J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.seizure.2017.05.001","article-title":"Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study","volume":"49","author":"Gujjar","year":"2017","journal-title":"Seizure"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.pediatrneurol.2014.07.021","article-title":"Efficacy and safety of IV levetiracetam in children with acute repetitive seizures","volume":"51","author":"Isguder","year":"2014","journal-title":"Pediatr. Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yebeh.2015.04.065","article-title":"Incidence and mortality of super-refractory status epilepticus in adults","volume":"49","author":"Kantanen","year":"2015","journal-title":"Epilepsy Behav."},{"key":"B27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.yebeh.2011.12.020","article-title":"Treatment of status epilepticus in a large community hospital","volume":"23","author":"Kellinghaus","year":"2012","journal-title":"Epilepsy Behav."},{"key":"B28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pediatrneurol.2010.11.005","article-title":"Use of intravenous levetiracetam for management of acute seizures in neonates","volume":"44","author":"Khan","year":"2011","journal-title":"Pediatr. Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1684\/epd.2017.0889","article-title":"Levetiracetam-induced thrombocytopenia in a patient with status epilepticus","volume":"19","author":"Kim","year":"2017","journal-title":"Epileptic Disord."},{"key":"B30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2009.02.016","article-title":"Role of intravenous levetiracetam in acute seizure management of children","volume":"41","author":"Kirmani","year":"2009","journal-title":"Pediatr. Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.pediatrneurol.2013.09.006","article-title":"Levetiracetam-induced anaphylaxis in a neonate","volume":"50","author":"Koklu","year":"2014","journal-title":"Pediatr. Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/epi.13584","article-title":"Costs and cost-driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from Germany","volume":"57","author":"Kortland","year":"2016","journal-title":"Epilepsia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.seizure.2015.03.018","article-title":"Intravenous levetiracetam in clinical practice\u2013Results from an independent registry","volume":"29","author":"Lang","year":"2015","journal-title":"Seizure"},{"key":"B34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3109\/00207454.2012.657376","article-title":"A systematic review of randomized controlled trials on the theraputic effect of intravenous sodium valproate in status epilepticus","volume":"122","author":"Liu","year":"2012","journal-title":"Int. J. Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13063-017-2010-8","article-title":"Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial","volume":"18","author":"Lyttle","year":"2017","journal-title":"Trials"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","article-title":"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial","volume":"393","author":"Lyttle","year":"2019","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/bjp.2008.198","article-title":"Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A","volume":"154","author":"Matagne","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"S456","DOI":"10.1007\/s12028-017-0465-9","article-title":"Shapshak AH. A case of rhabdomyolysis exacerbated by levetiracetam administration","volume":"27","author":"May","year":"2017","journal-title":"Neurocrit. Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.seizure.2012.05.010","article-title":"Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: Experience from a children's hospital","volume":"21","author":"McTague","year":"2012","journal-title":"Seizure"},{"key":"B40","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1468-1331.2009.02917.x","article-title":"EFNS guideline on the management of status epilepticus in adults","volume":"17","author":"Meierkord","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.eplepsyres.2008.05.004","article-title":"Tolerability and dosing experience of intravenous levetiracetam in children and infants","volume":"81","author":"Michaelides","year":"2008","journal-title":"Epilepsy Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00415-011-6227-2","article-title":"Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study","volume":"259","author":"Misra","year":"2012","journal-title":"J. Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jnnp.2008.145458","article-title":"Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus","volume":"80","author":"Moddel","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.04.013","article-title":"Management of generalised convulsive status epilepticus (SE): a prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam\u2013Pilot study","volume":"114","author":"Mundlamuri","year":"2015","journal-title":"Epilepsy Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1474-4422(15)00296-3","article-title":"Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial","volume":"15","author":"Navarro","year":"2016","journal-title":"Lancet Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.seizure.2019.01.015","article-title":"Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study","volume":"65","author":"Nene","year":"2019","journal-title":"Seizure"},{"key":"B47","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/0883073809348795","article-title":"Intravenous levetiracetam in children with seizures: a prospective safety study","volume":"25","author":"Ng","year":"2010","journal-title":"J. Child Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","article-title":"The economic cost of brain disorders in Europe","volume":"19","author":"Olesen","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.seizure.2004.06.001","article-title":"Estimating the economic burden of status epilepticus to the health care system","volume":"14","author":"Penberthy","year":"2005","journal-title":"Seizure"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003723.pub2","article-title":"Anticonvulsant therapy for status epilepticus","author":"Prasad","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003723.pub3","article-title":"Anticonvulsant therapy for status epilepticus","volume":"2014","author":"Prasad","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.jocn.2012.08.014","article-title":"Intravenous levetiracetam for treatment of neonatal seizures","volume":"20","author":"Rakshasbhuvankar","year":"2013","journal-title":"J. Clin. Neurosci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.pediatrneurol.2010.03.017","article-title":"Intravenous levetiracetam in the management of acute seizures in children","volume":"43","author":"Reiter","year":"2010","journal-title":"Pediatr. Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","article-title":"The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents","volume":"136","author":"Rigo","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.yebeh.2008.01.004","article-title":"Intravenous levetiracetam: treatment experience with the first 50 critically ill patients","volume":"12","author":"Ruegg","year":"2008","journal-title":"Epilepsy Behav."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e2339","DOI":"10.1212\/WNL.0000000000007503","article-title":"Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus","volume":"92","author":"S\u00e1nchez Fern\u00e1ndez","year":"2019","journal-title":"Neurology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1517\/14656566.2015.997212","article-title":"Therapeutic choices in convulsive status epilepticus","volume":"16","author":"Sanchez Fernandez","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"B58","first-page":"S63","article-title":"Levetiracetam Induced Increase in Creatine Phosphokinase Levels","volume":"27","author":"Shahbaz","year":"2017","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"B59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med. Res. Methodol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/j.1528-1167.2008.01706_3.x","article-title":"The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus","volume":"49","author":"Shorvon","year":"2008","journal-title":"Epilepsia"},{"key":"B61","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4103\/JPN.JPN_126_17","article-title":"IV Levetiracetam versus IV Phenytoin in childhood seizures: A randomized controlled trial","volume":"13","author":"Singh","year":"2018","journal-title":"J. Pediatr. Neurosci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3233\/JPN-2011-0458","article-title":"Levetiracetam for the treatment of pediatric status epilepticus: A case series","volume":"9","author":"Standish","year":"2011","journal-title":"J. Pediatr. Neurol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/1756285608100460","article-title":"New treatment options in status epilepticus: a critical review on intravenous levetiracetam","volume":"2","author":"Trinka","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B64","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.seizure.2016.11.001","article-title":"25 years of advances in the definition, classification and treatment of status epilepticus","volume":"44","author":"Trinka","year":"2017","journal-title":"Seizure"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2013Report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40265-015-0454-2","article-title":"Pharmacotherapy for Status Epilepticus","volume":"75","author":"Trinka","year":"2015","journal-title":"Drugs"},{"key":"B67","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1517\/14656566.2016.1127354","article-title":"Pharmacologic treatment of status epilepticus","volume":"17","author":"Trinka","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"B68","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1528-1167.2011.03232.x","article-title":"What is the evidence to use new intravenous AEDs in status epilepticus","volume":"52","author":"Trinka","year":"2011","journal-title":"Epilepsia"},{"key":"B69","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.seizure.2009.11.007","article-title":"Management of refractory status epilepticus at a tertiary care centre in a developing country","volume":"19","author":"Tripathi","year":"2010","journal-title":"Seizure"},{"key":"B70","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11060-010-0126-8","article-title":"A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures","volume":"99","author":"Usery","year":"2010","journal-title":"J. Neurooncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/0883073808331351","article-title":"Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study","volume":"24","author":"Wheless","year":"2009","journal-title":"J. Child Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.seizure.2013.12.007","article-title":"The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: A meta-analysis of published studies","volume":"23","author":"Yasiry","year":"2014","journal-title":"Seizure"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/NDT.S181886","article-title":"Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles","volume":"15","author":"Yi","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B74","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.seizure.2012.01.008","article-title":"Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: A systematic review","volume":"21","author":"Zelano","year":"2012","journal-title":"Seizure"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00751\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T03:34:06Z","timestamp":1722915246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00751\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":74,"alternative-id":["10.3389\/fphar.2020.00751"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00751","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"article-number":"751"}}